<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Pharmacol Toxicol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Pharmacol Toxicol</journal-id><journal-id journal-id-type="pmc-domain-id">1953</journal-id><journal-id journal-id-type="pmc-domain">bmcphartox</journal-id><journal-title-group><journal-title>BMC Pharmacology &amp; Toxicology</journal-title></journal-title-group><issn pub-type="epub">2050-6511</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11370030</article-id><article-id pub-id-type="pmcid-ver">PMC11370030.1</article-id><article-id pub-id-type="pmcaid">11370030</article-id><article-id pub-id-type="pmcaiid">11370030</article-id><article-id pub-id-type="pmid">39228002</article-id><article-id pub-id-type="doi">10.1186/s40360-024-00777-z</article-id><article-id pub-id-type="publisher-id">777</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Appropriate use of triazolam in elderly patients considering a quantitative benefit-risk assessment based on the pharmacokinetic-pharmacodynamic modeling and simulation approach supported by real-world data</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5740-4346</contrib-id><name name-style="western"><surname>Okada</surname><given-names initials="A">Akira</given-names></name><address><email>akiokada@musashino-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sera</surname><given-names initials="S">Shoji</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nagai</surname><given-names initials="N">Naomi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04bcbax71</institution-id><institution-id institution-id-type="GRID">grid.411867.d</institution-id><institution-id institution-id-type="ISNI">0000 0001 0356 8417</institution-id><institution>Laboratory of Regulatory Science, Faculty of Pharmacy, </institution><institution>Musashino University, </institution></institution-wrap>1&#8722;1&#8722;20 Shinmachi, Nishitokyo-shi, Tokyo 202&#8722;8585 Japan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04bcbax71</institution-id><institution-id institution-id-type="GRID">grid.411867.d</institution-id><institution-id institution-id-type="ISNI">0000 0001 0356 8417</institution-id><institution>Research Institute of Pharmaceutical Sciences, </institution><institution>Musashino University, </institution></institution-wrap>1&#8211;1&#8211;20 Shinmachi, Nishitokyo-shi, Tokyo 202&#8211;8585 Japan </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>9</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>25</volume><issue-id pub-id-type="pmc-issue-id">452279</issue-id><elocation-id>60</elocation-id><history><date date-type="received"><day>30</day><month>5</month><year>2023</year></date><date date-type="accepted"><day>7</day><month>8</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>03</day><month>09</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-05 09:25:41.230"><day>05</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="40360_2024_Article_777.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Triazolam is a typical drug commonly used in the elderly; however, there have been concerns about its adverse events resulting from age-related changes in physiological function and drug interactions with concomitant drugs. Thus, updated information contributing to the appropriate use based on the latest pharmacokinetic and post-marketing surveillance methods is needed. In this study, we evaluated the appropriate use of triazolam in the elderly by integrating real-world data with a modeling and simulation approach.</p></sec><sec><title>Methods</title><p id="Par2">The occurrence risk of adverse events in the elderly was evaluated using the spontaneous adverse event reporting regulatory databases from Japan and the United States. Information on drug concentrations and reactions was extracted from previous publications to estimate the threshold for plasma triazolam concentrations that cause adverse events. The pharmacokinetic/pharmacodynamic (PK/PD) model was then constructed, and the dose and administration were evaluated in various situations anticipated in medical practice.</p></sec><sec><title>Results</title><p id="Par3">Among all prescriptions, 25.4% were prescribed to individuals aged 80 years or above, and 51.8% were for those aged 70 years or above. A majority of cases involved CYP3A-metabolized drug combinations, accounting for 85.6%. Elderly individuals were at a higher risk of developing delirium and fall-fracture. Based on the constructed PK/PD model, the risk of adverse events increased when the plasma concentration of triazolam exceeded the calculated threshold of 0.44 ng/mL at approximately 6&#160;h after administration. Administering 0.125&#160;mg of triazolam, is half the approved dose for the elderly in Japan was deemed appropriate. Moreover, there was a substantial risk of adverse events even at a dosage of 0.0625&#160;mg in combination with a moderate or strong inhibitor of cytochrome P450 3&#160;A.</p></sec><sec><title>Conclusion</title><p id="Par4">Analyzing large-scale databases and existing research publications on PK/PD can practically contribute to optimizing triazolam drug therapy for the elderly in the daily clinical setting.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s40360-024-00777-z.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Adverse events</kwd><kwd>Elderly</kwd><kwd>Modeling and simulation</kwd><kwd>Triazolam</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>19K20736</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par15">Population aging has become an issue in many countries, and drug therapy for the elderly is becoming increasingly important. The elderly are prone to potential safety issues resulting from many factors, such as age-related decline in liver and kidney function [<xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR3">3</xref>] and polypharmacy [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. To improve drug therapy for the elderly, guidelines on the appropriate use of pharmaceuticals have been issued in Japan [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]; however, generally, the elderly do not participate in clinical studies and there is insufficient data on drug dosing, including dosage and administration adjustments for pharmaceuticals. Therefore, it is necessary to generate new information to improve drug therapy that considers the unique characteristics of the elderly.</p><p id="Par16">Chronic insomnia is common in the elderly [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>], and triazolam, a short-acting benzodiazepine receptor agonist, is frequently prescribed [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. However, triazolam poses the risk of inducing geriatric syndromes, such as amnesia; thus, it is necessary to avoid using it as much as possible [<xref ref-type="bibr" rid="CR12">12</xref>&#8211;<xref ref-type="bibr" rid="CR14">14</xref>]. In addition, benzodiazepine hypnotics have a prolonged half-life in the elderly [<xref ref-type="bibr" rid="CR15">15</xref>&#8211;<xref ref-type="bibr" rid="CR17">17</xref>]. Greenblatt et al. observed an increase in plasma triazolam concentration with reduced clearance in the elderly when triazolam was administered to young people (mean, 30 years) and the elderly (mean, 69 years). They also reported that indicators of delirium and cognitive function correlated with changes in plasma concentration [<xref ref-type="bibr" rid="CR18">18</xref>]. Therefore, when using triazolam in the elderly, there is a higher risk of developing adverse events associated with exposure to high drug concentrations; thus, the practice of more thorough drug treatments is required. However, triazolam has been on the market for a long time and is used based on the experience of healthcare professionals in many cases, so it is a major issue to update information contributing to its proper use.</p><p id="Par17">Epidemiological studies that evaluate the appropriate use of pharmaceuticals and research that reexamine the available data have received a lot of attention recently. In particular, post-marketing pharmacovigilance has become important [<xref ref-type="bibr" rid="CR19">19</xref>], and the use of large-scale databases is essential for analyzing the safety information of pharmaceuticals. In addition, spontaneous adverse event reporting databases are publicly available in the United States and Japan, which reflect the real-world. They have made it possible to gather data on age groups and lengths of therapy, such as data on elderly patients that is not often available through clinical trials. The pharmaceutical evaluation method of modeling and simulation is also widely used, from pharmaceutical development to actual clinical practice. It contributes significantly to the prediction of the efficacy and adverse events of pharmaceuticals [<xref ref-type="bibr" rid="CR20">20</xref>]. These methodologies allow for the extraction and evaluation of previously unidentified issues and trends.</p><p id="Par18">This study aimed to provide evidence that contributes to the optimization of triazolam drug therapy in the elderly by integrating spontaneous adverse event reporting databases with existing information on pharmacokinetics and pharmacodynamics.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Data sources</title><p id="Par19">To analyze triazolam prescriptions and patient age distribution, we extracted claims data from April 2014 to March 2018 from Japan&#8217;s National Database of Health Insurance Claims and Specific Health Checkups (NDB), published by the Ministry of Health, Labor, and Welfare. To comprehensively assess the appropriate use of triazolam, we first evaluated adverse event spontaneous reporting data that reflected the medical practice in Japan and also considered information on similar databases in the United States. Both the Japanese Adverse Drug Event Report database (JADER) and the FDA Adverse Event Reporting System (FAERS) were utilized to analyze a wide range of adverse event data from both databases, covering the period from April 2004 to March 2019. Adverse event data in patients receiving triazolam were analyzed to evaluate concomitant drug use using information from JADER. For pharmacokinetic interactions, using the University of Washington Drug Interaction Database, drugs with an area under the blood concentration-time curve increase ratio (AUCR) after triazolam dosing of 1.25 times or greater were extracted and are listed in Table&#160;<xref rid="Tab1" ref-type="table">1</xref> [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par20">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Drug-drug interaction for triazolam</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Interacting drug</th><th align="left" colspan="1" rowspan="1">AUCR</th><th align="left" colspan="1" rowspan="1">Ref.</th></tr></thead><tbody><tr><td align="left" colspan="3" rowspan="1">Antidepressant</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Nefazodone</td><td align="left" colspan="1" rowspan="1">3.90</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR26">26</xref>]</td></tr><tr><td align="left" colspan="3" rowspan="1">Antibiotics</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Clarithromycin</td><td align="left" colspan="1" rowspan="1">5.26</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR27">27</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Erythromycin</td><td align="left" colspan="1" rowspan="1">3.80</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR27">27</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Troleandomycin</td><td align="left" colspan="1" rowspan="1">3.76</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR28">28</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Isoniazid</td><td align="left" colspan="1" rowspan="1">1.46</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR29">29</xref>]</td></tr><tr><td align="left" colspan="3" rowspan="1">Antifungals</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Itraconazole</td><td align="left" colspan="1" rowspan="1">27.1</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Ketoconazole</td><td align="left" colspan="1" rowspan="1">22.4</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Fluconazole</td><td align="left" colspan="1" rowspan="1">4.42</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR31">31</xref>]</td></tr><tr><td align="left" colspan="3" rowspan="1">Protease Inhibitor</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Ritonavir</td><td align="left" colspan="1" rowspan="1">40.7</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR32">32</xref>]</td></tr><tr><td align="left" colspan="3" rowspan="1">H<sub>2</sub> Receptor Antagonists</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Cimetidine</td><td align="left" colspan="1" rowspan="1">2.20</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR33">33</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Ranitidine</td><td align="left" colspan="1" rowspan="1">1.31</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR34">34</xref>]</td></tr><tr><td align="left" colspan="3" rowspan="1">Calcium Channel Blockers</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Mibefradil</td><td align="left" colspan="1" rowspan="1">8.36</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR35">35</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Diltiazem</td><td align="left" colspan="1" rowspan="1">3.38</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR36">36</xref>]</td></tr><tr><td align="left" colspan="3" rowspan="1">Other drugs</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Grapefruit juice</td><td align="left" colspan="1" rowspan="1">2.43</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR37">37</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hormonal contraceptives</td><td align="left" colspan="1" rowspan="1">1.44</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR38">38</xref>]</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">AUCR</italic> ratio of area under the curve (AUC) in the presence of an interacting drug to that in the absent, <italic toggle="yes">AUCR</italic> triazolam AUC with precipitant / triazolam AUC without precipitant</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec4"><title>Definitions of adverse events</title><p id="Par21">Fall-fracture, delirium, disturbed consciousness, liver disorders, renal disorders, gastrointestinal disorders, and hypoglycemia were extracted as the seven typical adverse events associated with triazolam in the elderly [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Based on the terminology described in the Medical Dictionary for Regulatory Activities Japanese version (MedDRA/J, version 22.0), adverse events were classified using the preferred terms listed below the classification. To determine the occurrence risk of adverse events, the cut-off age was set at 70 and 80 years, and the evaluation was performed with reporting odds ratio (ROR) and 95% confidence interval (95% CI) in the elderly versus the non-elderly. The signal detection criteria for adverse event occurrence was determined as 95%CI&#8201;&gt;&#8201;1.</p></sec><sec id="Sec5"><title>Pharmacokinetic-pharmacodynamic modeling</title><p id="Par22">To obtain information on changes in triazolam blood concentration and drug susceptibility (sedation and cognitive function), we extracted the mean value of each from the report by Greenblatt et al. [<xref ref-type="bibr" rid="CR18">18</xref>] using WebPlot Digitizer version 4.3 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://automeris.io/WebPlotDigitizer/">https://automeris.io/WebPlotDigitizer/</ext-link>). Since the original literature used as a reference for the analysis provided only mean values of blood concentration time course obtained from information on young and elderly subjects (30 years old, 72&#160;kg and 69 years old, 69&#160;kg), the effect of age was incorporated in a general power law form in the pharmacokinetic-pharmacodynamic (PK/PD) model based on this literature information [<xref ref-type="bibr" rid="CR18">18</xref>]:</p><p id="Par23">
<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\text{clearance}} = {{{\theta }}_{{\text{clearance}}}} \times {\left( {\frac{{{\text{age}}}}{{30}}} \right)^{{{\theta{\text{cov}}}}}}$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="40360_2024_777_Article_Equ1.gif"/></alternatives></disp-formula>
</p><p id="Par24">where &#952; is the estimated value of parameters. The basic pharmacokinetic model used in this study is a one-compartment model; when the dose is constant, the inverse of AUCR was added as a covariate of clearance. We set the threshold for drug susceptibility at the value where the fluctuation was less than 10% compared to the value with the largest fluctuation. This threshold was based on the signal-to-noise ratio of 10, a predominantly used lower limit in quantification, and previous results [<xref ref-type="bibr" rid="CR18">18</xref>] showing minimal PD fluctuation in placebo and baseline regression post-triazolam administration. We calculated the blood concentration during the development of drug susceptibility using receiver-operating characteristic (ROC) analysis for values below this threshold. A PK/PD model was developed using a nonlinear regression model to estimate changes in drug susceptibility versus blood concentration. Both direct response and effect compartment models were considered for the PD model, with testing conducted for linear and Emax models, respectively. In the setting of the error model, inter-individual variability was not estimated, and the proportional error model (Eq.&#160;<xref rid="Equ2" ref-type="disp-formula">2</xref>) was used for the PK model. In contrast, the additive error model (Eq.&#160;<xref rid="Equ3" ref-type="disp-formula">3</xref>) was used for the PD model as residual variability:</p><p id="Par25">
<disp-formula id="Equ2"><label>2</label><alternatives><tex-math id="M2">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\text{Obserbatio}}{{\text{n}}_{\text{j}}}={\text{Predictio}}{{\text{n}}_{\text{j}}} \times \left( {1+{\varepsilon}} \right)$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="40360_2024_777_Article_Equ2.gif"/></alternatives></disp-formula>
</p><p id="Par26">
<disp-formula id="Equ3"><label>3</label><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${\text{Obserbatio}}{{\text{n}}_{\text{j}}}={\text{Predictio}}{{\text{n}}_{\text{j}}}+{\varepsilon}$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" orientation="portrait" xlink:href="40360_2024_777_Article_Equ3.gif"/></alternatives></disp-formula>
</p><p id="Par27">Obserbation<sub>j</sub> and Prediction<sub>j</sub> are the j<sup>th</sup> observation and prediction, respectively, whereas &#949; denotes a random variable following a normal distribution with a mean of 0 and a variance of &#963;<sup>2</sup>. The validity of the model was determined using a coefficient of variation (CV%) of the estimated values, objective function value (OFV), goodness-of-fit plots and Akaike&#8217;s information criterion. The NLME software (version 8.1; Certara, St. Louis, MO, USA) was used for model construction, parameter estimation, and simulation.</p></sec><sec id="Sec6"><title>Simulation</title><p id="Par28">The following estimates in different age groups during the combined use of typical drugs were evaluated by simulation using the constructed final model:</p><p id="Par29">I: Estimation of the time required for blood concentration after 0.25&#160;mg of triazolam dosing to decrease to the threshold in healthy young people.</p><p id="Par30">II: Estimation of acceptable triazolam dose and administration, in which the blood concentration reaches the threshold at the time estimated by I in the elderly.</p><p id="Par31">III: Estimation of changes in blood concentration during the combined use of 0.0625&#160;mg of triazolam and various cytochrome P450 (CYP) 3&#160;A inhibitors and estimation of the acceptable AUCR range, in which the blood concentration reaches the threshold at the time estimated by I in the elderly.</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par32">The R Commander Plug-in for the EZR package version 4.0.2 (RcmdrPlugin.EZR) was used for statistical analyses [<xref ref-type="bibr" rid="CR25">25</xref>].</p></sec></sec><sec id="Sec8" sec-type="results"><title>Results</title><p id="Par33">The quantity of triazolam prescribed in Japan from April 2014 to March 2018 was 181.6&#8201;&#8722;&#8201;275.9&#160;million tablets per year, and no particular trend was observed in the age distribution of patients prescribed with triazolam between the years. Of all prescriptions, 25.4% were for individuals aged 80 years or above, and 51.8% were for those aged 70 years or above. In addition, only 2.3% of all prescriptions were for individuals under 30 years of age. Among all of the JADER data, there were 4116 entries containing triazolam, which was the 97th highest among all drugs registered in JADER, after the hypnotic sedatives brotizolam, zolpidem, etizolam, and flunitrazepam. There were many combinations containing benzodiazepines and cases of drug combinations involving CYP3A in metabolism, accounting for the majority at 3542 cases (85.6%). Fifteen drugs were extracted as drugs with an AUCR of 1.25-fold or greater (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Of these, there were 354 cases (8.6%) of combinations with triazolam. Among these, there were 78 cases of combinations with clarithromycin, 16 cases with itraconazole, and no case with ritonavir, respectively, which are strong CYP3A inhibitors [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. There were 78 cases of combination with diltiazem, 14 cases with fluconazole, and 8 cases with erythromycin, respectively, which are moderate CYP3A inhibitors [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par34">Table&#160;<xref rid="Tab2" ref-type="table">2</xref> shows the occurrence risk of adverse events in JADER and FAERS, and triazolam was reported as the suspected drug in 784 and 36,770 adverse events, respectively. Occurrence signals were detected in the elderly because of delirium, fall-fracture, and renal disorders. In particular, delirium exhibited a higher ROR for age 70 years or above compared with the other adverse events, which were 7.7 in JADER and 2.6 in FAERS. In addition, although JADER had a smaller number of cases and calculated ROR values tended to be higher compared with FAERS, the two regulatory databases demonstrated similar trends in terms of the categories of adverse events detected.</p><p id="Par35">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Signals of adverse events of triazolam in patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3" colspan="1">Averse events</th><th align="left" colspan="5" rowspan="1">JADER</th><th align="left" colspan="5" rowspan="1">FAERS</th></tr><tr><th align="left" rowspan="2" colspan="1">Total</th><th align="left" colspan="2" rowspan="1">Cut-off age</th><th align="left" colspan="2" rowspan="1">Reporting odds ratio (95% CI)</th><th align="left" rowspan="2" colspan="1">Total</th><th align="left" colspan="2" rowspan="1">Cut-off age</th><th align="left" colspan="2" rowspan="1">Reporting odds ratio (95% CI)</th></tr><tr><th align="left" colspan="1" rowspan="1">&#8805;&#8201;80</th><th align="left" colspan="1" rowspan="1">&#8805;&#8201;70</th><th align="left" colspan="1" rowspan="1">80 years</th><th align="left" colspan="1" rowspan="1">70 years</th><th align="left" colspan="1" rowspan="1">&#8805;&#8201;80</th><th align="left" colspan="1" rowspan="1">&#8805;&#8201;70</th><th align="left" colspan="1" rowspan="1">80 years</th><th align="left" colspan="1" rowspan="1">70 years</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Consciousness disturbed</td><td char="." align="char" colspan="1" rowspan="1">110</td><td char="." align="char" colspan="1" rowspan="1">9</td><td char="." align="char" colspan="1" rowspan="1">24</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">0.6 (0.3&#8201;&#8722;&#8201;1.2)</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">0.8 (0.5&#8201;&#8722;&#8201;1.3)</td><td char="." align="char" colspan="1" rowspan="1">679</td><td char="." align="char" colspan="1" rowspan="1">119</td><td char="." align="char" colspan="1" rowspan="1">282</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">1.7 (1.4&#8201;&#8722;&#8201;2.1)*</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">1.9 (1.6&#8201;&#8722;&#8201;2.2)*</td></tr><tr><td align="left" colspan="1" rowspan="1">Liver disorders</td><td char="." align="char" colspan="1" rowspan="1">61</td><td char="." align="char" colspan="1" rowspan="1">2</td><td char="." align="char" colspan="1" rowspan="1">11</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">0.2 (0.1&#8201;&#8722;&#8201;0.9)</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">0.6 (0.3&#8201;&#8722;&#8201;1.3)</td><td char="." align="char" colspan="1" rowspan="1">1363</td><td char="." align="char" colspan="1" rowspan="1">204</td><td char="." align="char" colspan="1" rowspan="1">470</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">1.4 (1.2&#8201;&#8722;&#8201;1.7)*</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">1.4 (1.2&#8201;&#8722;&#8201;1.5)*</td></tr><tr><td align="left" colspan="1" rowspan="1">Delirium</td><td char="." align="char" colspan="1" rowspan="1">33</td><td char="." align="char" colspan="1" rowspan="1">13</td><td char="." align="char" colspan="1" rowspan="1">23</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">5.2 (2.5&#8201;&#8722;&#8201;10.7)*</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">7.7 (3.6&#8201;&#8722;&#8201;16.5)*</td><td char="." align="char" colspan="1" rowspan="1">254</td><td char="." align="char" colspan="1" rowspan="1">50</td><td char="." align="char" colspan="1" rowspan="1">127</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">2.0 (1.4&#8201;&#8722;&#8201;2.7)*</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">2.6 (2.0&#8201;&#8722;&#8201;3.3)*</td></tr><tr><td align="left" colspan="1" rowspan="1">Gastrointestinal disorders</td><td char="." align="char" colspan="1" rowspan="1">33</td><td char="." align="char" colspan="1" rowspan="1">8</td><td char="." align="char" colspan="1" rowspan="1">13</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">2.4 (1.0&#8201;&#8722;&#8201;5.4)*</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">2.0 (0.9&#8201;&#8722;&#8201;4.1)</td><td char="." align="char" colspan="1" rowspan="1">2310</td><td char="." align="char" colspan="1" rowspan="1">314</td><td char="." align="char" colspan="1" rowspan="1">704</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">1.3 (1.1&#8201;&#8722;&#8201;1.4)*</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">1.1 (1.0&#8201;&#8722;&#8201;1.3)*</td></tr><tr><td align="left" colspan="1" rowspan="1">Hypoglycemia</td><td char="." align="char" colspan="1" rowspan="1">21</td><td char="." align="char" colspan="1" rowspan="1">3</td><td char="." align="char" colspan="1" rowspan="1">3</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">1.2 (0.3&#8201;&#8722;&#8201;4.1)</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">0.5 (0.2&#8201;&#8722;&#8201;1.7)</td><td char="." align="char" colspan="1" rowspan="1">115</td><td char="." align="char" colspan="1" rowspan="1">15</td><td char="." align="char" colspan="1" rowspan="1">46</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">1.2 (0.7&#8201;&#8722;&#8201;2.1)</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">1.7 (1.2&#8201;&#8722;&#8201;2.5)*</td></tr><tr><td align="left" colspan="1" rowspan="1">Fall-fracture</td><td char="." align="char" colspan="1" rowspan="1">20</td><td char="." align="char" colspan="1" rowspan="1">7</td><td char="." align="char" colspan="1" rowspan="1">10</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">4.0 (1.6&#8201;&#8722;&#8201;10.4)*</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">3.1 (1.3&#8201;&#8722;&#8201;7.6)*</td><td char="." align="char" colspan="1" rowspan="1">522</td><td char="." align="char" colspan="1" rowspan="1">92</td><td char="." align="char" colspan="1" rowspan="1">228</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">1.7 (1.4&#8201;&#8722;&#8201;2.2)*</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">2.0 (1.7&#8201;&#8722;&#8201;2.4)*</td></tr><tr><td align="left" colspan="1" rowspan="1">Renal disorders</td><td char="." align="char" colspan="1" rowspan="1">17</td><td char="." align="char" colspan="1" rowspan="1">7</td><td char="." align="char" colspan="1" rowspan="1">9</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">5.3 (2.0&#8201;&#8722;&#8201;14.2)*</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">3.5 (1.3&#8201;&#8722;&#8201;9.2)*</td><td char="." align="char" colspan="1" rowspan="1">705</td><td char="." align="char" colspan="1" rowspan="1">131</td><td char="." align="char" colspan="1" rowspan="1">272</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">1.8 (1.5&#8201;&#8722;&#8201;2.2)*</td><td char="&#x2212;" align="char" colspan="1" rowspan="1">1.6 (1.4&#8201;&#8722;&#8201;1.9)*</td></tr><tr><td align="left" colspan="1" rowspan="1">Total</td><td char="." align="char" colspan="1" rowspan="1">784</td><td char="." align="char" colspan="1" rowspan="1">97</td><td char="." align="char" colspan="1" rowspan="1">196</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">36,770</td><td char="." align="char" colspan="1" rowspan="1">4094</td><td char="." align="char" colspan="1" rowspan="1">10,269</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">95%CI</italic> 95% confidence interval, <italic toggle="yes">JADER</italic> Japanese adverse drug event report, <italic toggle="yes">FAERS</italic> Food and Drug Administration Adverse Event Reporting System. *<italic toggle="yes">P</italic>, &#8804;&#8201;0.05</p></table-wrap-foot></table-wrap>
</p><p id="Par36">Table&#160;<xref rid="Tab3" ref-type="table">3</xref> lists the estimated parameters for the resulting PK/PD model. For the PK model, a one-compartment model including a first-order absorption process best representing the changes in blood concentration and age was incorporated into distribution volume and clearance, respectively, as a covariate. For the PD model, an anti-clockwise hysteresis loop was observed between blood concentration and drug efficacy; therefore, an effect compartment model was adopted to eliminate the time difference. Furthermore, a drug susceptibility against concentration in the effect compartment exhibited a positive linear correlation. The OFV values during the model building process were OFV 223.5 for the linear and OFV 225.2 for the Emax in the direct response model. Compared to the direct response model, OFV 193.7 in the effect compartment model showed a significantly lower OFV and, therefore, was determined as the more appropriate model. The parameters and structure of the PK/PD model had a low CV% of 1.05&#8201;&#8722;&#8201;21.8%, and the goodness-of-fit plots between values estimated from the model and extracted values indicated the appropriate model fitting and valid (<xref rid="MOESM1" ref-type="media">Supplemental fig</xref>). The threshold for sedation and cognitive function deterioration were 0.44 and 0.58 ng/mL, with the resulting sensitivity values of 0.85 and 1.00 and specificity values of 0.90 and 1.00, respectively.</p><p id="Par37">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Population pharmacokinetic/pharmacodynamic parameters of triazolam</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Parameter (unit)</th><th align="left" colspan="1" rowspan="1">Estimate</th><th align="left" colspan="1" rowspan="1">CV%</th></tr></thead><tbody><tr><td align="left" colspan="3" rowspan="1">
<bold>Pharmacokinetic model</bold>
</td></tr><tr><td align="left" colspan="3" rowspan="1">Population mean</td></tr><tr><td align="left" colspan="3" rowspan="1">&#8195;Ka&#8201;=&#8201;&#952;1</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8195;&#952;1 (1/hr)</td><td align="left" colspan="1" rowspan="1">3.16</td><td align="left" colspan="1" rowspan="1">5.27</td></tr><tr><td align="left" colspan="3" rowspan="1">&#8195;Vd&#8201;=&#8201;&#952;2&#215; (age/30)<sup>&#952;4</sup></td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8195;&#952;2 (L)</td><td align="left" colspan="1" rowspan="1">119</td><td align="left" colspan="1" rowspan="1">1.86</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8195;&#952;4</td><td align="left" colspan="1" rowspan="1">&#8722;0.49</td><td align="left" colspan="1" rowspan="1">6.53</td></tr><tr><td align="left" colspan="3" rowspan="1">&#8195;CL&#8201;=&#8201;&#952;3 &#215; (age/30)<sup>&#952;5</sup> &#215; 1/AUCR</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8195;&#952;3 (L/hr/kg)</td><td align="left" colspan="1" rowspan="1">0.47</td><td align="left" colspan="1" rowspan="1">1.92</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8195;&#952;5</td><td align="left" colspan="1" rowspan="1">&#8722;0.53</td><td align="left" colspan="1" rowspan="1">4.30</td></tr><tr><td align="left" colspan="3" rowspan="1">Residual variability</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8195;&#963; (%)</td><td align="left" colspan="1" rowspan="1">6.20</td><td align="left" colspan="1" rowspan="1">10.8</td></tr><tr><td align="left" colspan="3" rowspan="1">
<bold>Pharmacodynamic model</bold>
</td></tr><tr><td align="left" colspan="3" rowspan="1">Population mean</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8195;Keo (1/hr)</td><td align="left" colspan="1" rowspan="1">3.42</td><td align="left" colspan="1" rowspan="1">12.6</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8195;Sedation constant</td><td align="left" colspan="1" rowspan="1">12.1</td><td align="left" colspan="1" rowspan="1">1.05</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8195;Cognitive function constant</td><td align="left" colspan="1" rowspan="1">&#8722;11.0</td><td align="left" colspan="1" rowspan="1">3.14</td></tr><tr><td align="left" colspan="1" rowspan="1">Residual variability</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8195;&#963; Sedation (mm)</td><td align="left" colspan="1" rowspan="1">6.81</td><td align="left" colspan="1" rowspan="1">21.8</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;&#8195;&#963; Cognitive function (%)</td><td align="left" colspan="1" rowspan="1">3.27</td><td align="left" colspan="1" rowspan="1">14.5</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">AUCR</italic> area under the blood concentration-time curve increase ratio; <italic toggle="yes">CV</italic> coefficient of variation; <italic toggle="yes">CL</italic> clearance; <italic toggle="yes">Ka</italic> first-order absorption rate constant; <italic toggle="yes">Keo</italic> plasma-effect compartment equilibration rate constant; <italic toggle="yes">Vd</italic> distribution volume; <italic toggle="yes">&#952;</italic> population mean; <italic toggle="yes">&#963;</italic> residual variability. Sedation&#8201;=&#8201;12.1 &#215; concentration, Cognitive function = &#8722;11.0 &#215; concentration</p></table-wrap-foot></table-wrap>
</p><p id="Par38">Based on the results of a simulation, 5.95&#160;h was required for blood concentration after a 0.25&#160;mg dose of triazolam in healthy young people to fall below 0.44 ng/mL (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). In contrast, when triazolam was administered to the elderly, 0.15&#160;mg was required for blood concentration to fall below 0.44 ng/mL after 5.95&#160;h. In addition, when 0.0625&#160;mg (half of a 0.125&#160;mg tablet) was administered to the elderly, the blood concentration was 0.44 ng/mL after 5.95&#160;h, and a concomitant AUCR of 2.27 was observed (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). The larger the AUCR of the drug, the more delayed the elimination. The half-life of triazolam with an AUCR of 1.0 was 2.9&#160;h, whereas the half-life of itraconazole with an AUCR of 27.1 was 69.8&#160;h.</p><p id="Par39">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Simulated Plasma Triazolam Concentration-time Profile in young and elderly patients. Dashed lines: 30 years old (dosage: 0.250 and 0.125&#160;mg/body), solid lines: 69 years old (dosage: 0.250, 0.125, and 0.0625&#160;mg/body). Dotted lines (horizontal axis): cut-off concentration (0.44&#160;&#181;g/mL), dotted lines (vertical axis): time required to reach cut-off concentration in young patients (5.95&#160;h)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1089" position="float" orientation="portrait" xlink:href="40360_2024_777_Fig1_HTML.jpg"/></fig>
</p><p id="Par40">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Plasma triazolam concentration, sedation, and cognitive function versus time profiles in elderly patients, when combined with CYP3A inhibitors. Cut-off concentration: 0.44&#160;&#181;g/mL, time required to reach cut-off concentration in young patients: 5.95&#160;h. Dosage: 0.0625&#160;mg/body (69 years old). Red line, AUCR&#8201;=&#8201;27.1 (itraconazole); orange line, 5.26 (clarithromycin); green line, 3.38 (diltiazem); blue line (0.44 ng/mL after 5.95 h), 2.27; and purple line, 1. AUCR: area under the concentration-time curve ratio</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1101" position="float" orientation="portrait" xlink:href="40360_2024_777_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec9" sec-type="discussion"><title>Discussion</title><p id="Par41">In this study, the appropriate use of triazolam in the elderly was evaluated using a modeling and simulation approach, supported by real-world data. Triazolam has been on the market for a long time, and more information regarding its efficacy and safety has been collected following its manufacturing and marketing, compared with the approval and application phase. The approach proposed in this study on prescription status, adverse event reporting, and dose adjustment using modeling and simulation proved particularly useful for such drugs.</p><p id="Par42">Fall-related fractures in the elderly greatly impact their quality of life and pose a risk of inducing fatal diseases, such as bedriddenness and aspiration pneumonia; thus, prevention is particularly important [<xref ref-type="bibr" rid="CR39">39</xref>]. As triazolam has a very short half-life of 2.9&#160;h and the effect of carry-over to the next morning is considered small, it tends to be more commonly used on the elderly compared with long-acting benzodiazepines. However, it has also been reported that the risk of falls is the same regardless of half-life or the presence or absence of a benzodiazepine skeleton [<xref ref-type="bibr" rid="CR40">40</xref>]. Thus, there is no consensus on the effects of factors such as half-life on falls. In the present study, the occurrence signals of fall-fracture after triazolam dosing were detected in both JADER and FAERS at 70 or 80 years and above. Therefore, the results supported that of previous reports, in which dosing of triazolam in the elderly above 70 years old poses a fall risk and the Guidance of Appropriate Medication for Elderly Patients notified in May 2018 [<xref ref-type="bibr" rid="CR6">6</xref>] and Jun 2019 [<xref ref-type="bibr" rid="CR7">7</xref>] in Japan.</p><p id="Par43">We constructed a PK/PD model to determine the relationship between changes in blood concentration after triazolam dosing in the elderly and pharmacodynamic events such as sedation and cognitive function. Blood concentration and pharmacological events are highly correlated [<xref ref-type="bibr" rid="CR18">18</xref>], and the transfer half-life from the blood to sites of action was also rapid at 6.9&#160;min. Thus, using blood concentration to indicate pharmacological events is considered useful. Interestingly, pharmacological events rarely occur when the blood concentration falls below the threshold. If it falls below the threshold within the period from dosing to waking up, the occurrence risk of fall-fracture may be reduced. In the present study, the threshold was estimated to be 0.44 ng/mL. When 0.25&#160;mg of triazolam was administered to healthy young people (30 years), it took 5.95&#160;h to decrease below the threshold. In other words, the blood triazolam concentration falls below the threshold when an individual wakes up. In contrast, when 0.25&#160;mg of triazolam was administered to the elderly, it took 7.80&#160;h to reach a threshold and blood triazolam concentration was not sufficiently reduced at waking time, suggesting that the risk of adverse events resulting from carry-over is increased. Next, we estimated that a dose of 0.156-mg triazolam was required for the concentration to fall below the threshold in the elderly at the same time as in healthy young people (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). In the package insert, a warning is included that states, &#8220;in the elderly, dosing should be started from a low dose.&#8221; However, the specific dose for the elderly is not mentioned. Based on the results of this study, we suggest that dosing at a half-dose (0.125&#160;mg) significantly reduced the risk of carry-over.</p><p id="Par44">Polypharmacy, aimed at treating comorbidities, is common in the elderly [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>], and changes in blood concentration tend to be affected by other pharmaceuticals. Itraconazole, a CYP3A inhibitor, and human immunodeficiency virus protease inhibitors are contraindicated for combined use, while diltiazem and clarithromycin are considered medications to be used with caution. [<xref ref-type="bibr" rid="CR41">41</xref>], it is necessary to pay attention to potential drug-drug interactions when administering triazolam in clinical settings for drug treatment. In the present study, we simulated changes in blood triazolam concentration and pharmacological events in the elderly when used in combination with diltiazem, clarithromycin, and itraconazole, whose combined use was reported in JADER, which is the adverse event report from medical settings in Japan (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>). In addition, even though the dose was set at 0.0625&#160;mg, which is 1/4 of the usual dose, blood concentration did not decrease sufficiently when combined with pharmaceuticals with an AUCR exceeding 2.27, even when administered at a low dose outside the approved dose range, which suggests the possibility of carry-over. Therefore, it is desirable to avoid using triazolam when administering medications with inhibition activity on CYP3A to the elderly and to consider alternative medications instead.</p><p id="Par45">There were several limitations to our study. Firstly, the published adverse events and judgment on the involvement of pharmaceuticals are at the discretion of the reporters who judge the involvement of pharmaceuticals, and there is also missing information, such as age. Secondly, there were many confounding factors present in this study, such as concomitant drugs and dose and unavoidable selection bias. Thirdly, ROR was exploratorily used as a qualitative signal; thus, quantitative evaluations, such as occurrence frequency, are impossible. Finally, in the PK/PD model, the effect of age was assumed to be linear, and indications for ages other than 30 or 69 years, as described in previous reports, are unknown.</p></sec><sec id="Sec10" sec-type="conclusion"><title>Conclusion</title><p id="Par46">In this study, based on available information from medical settings in Japan, notable adverse events associated with triazolam dosing in the elderly (delirium, fall-fracture) were extracted. Constructing a PK/PD model using age as a covariate allowed for establishing a dosing strategy for elderly patients using concurrent medications. Triazolam is frequently prescribed for elderly patients, and the findings will help with the optimal dose.</p></sec><sec sec-type="supplementary-material"><sec id="Sec11"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="40360_2024_777_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>95% CI</term><def><p id="Par5">95% confidence interval</p></def></def-item><def-item><term>AUCR</term><def><p id="Par6">Area under the blood concentration-time curve increase ratio</p></def></def-item><def-item><term>CV</term><def><p id="Par7">Coefficient of variation</p></def></def-item><def-item><term>CYP</term><def><p id="Par8">Cytochrome P450</p></def></def-item><def-item><term>FAERS</term><def><p id="Par9">FDA Adverse Event Reporting System</p></def></def-item><def-item><term>JADER</term><def><p id="Par10">Japanese Adverse Drug Event Report database</p></def></def-item><def-item><term>NDB</term><def><p id="Par11">National Database of Health Insurance Claims and Specific Health Checkups of Japan</p></def></def-item><def-item><term>OFV</term><def><p id="Par12">Objective function value</p></def></def-item><def-item><term>PK/PD</term><def><p id="Par13">Pharmacokinetic-pharmacodynamic</p></def></def-item><def-item><term>ROR</term><def><p id="Par14">Reporting odds ratio</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This study was supported by a Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Young Scientists, Grant Number 19K20736 (AO). The authors thank Ms. Natsuko Takano from Musashino University for assisting in the collection of some data for this study.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>AO and NN contributed equally to the conception, design of the research, and acquisition of the data; AO and SS contributed to the analysis of the data. All the authors critically revised the manuscript, and read and approved the final manuscript, and agree to be fully accountable for ensuring the integrity and accuracy of the work.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was supported by a Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Young Scientists, Grant Number 19K20736 (AO).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>JADER, FAERS, NDB open data Japan, and DIDB data files can be downloaded from [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.pmda.go.jp/safety/info-services/drugs/adr-info/suspected-adr/0004.html">https://www.pmda.go.jp/safety/info-services/drugs/adr-info/suspected-adr/0004.html</ext-link> (Accessed 2020-08-20, Japanese)], [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases">https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases</ext-link> (Accessed 2020-08-20]), [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000177182.html">https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000177182.html</ext-link> (Accessed 2020-08-20, Japanese)], and [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.druginteractionsolutions.org/">https://www.druginteractionsolutions.org/</ext-link> (Accessed 2020-08-20)].</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par47">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par48">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par49">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mangoni</surname><given-names>AA</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>SH</given-names></name></person-group><article-title>Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications</article-title><source>Br J Clin Pharmacol</source><year>2004</year><volume>57</volume><issue>1</issue><fpage>6</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2125.2003.02007.x</pub-id><pub-id pub-id-type="pmid">14678335</pub-id><pub-id pub-id-type="pmcid">PMC1884408</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6&#8211;14.<pub-id pub-id-type="pmid">14678335</pub-id><pub-id pub-id-type="doi">10.1046/j.1365-2125.2003.02007.x</pub-id><pub-id pub-id-type="pmcid">PMC1884408</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanigawara</surname><given-names>Y</given-names></name></person-group><article-title>Recent advances in pharmacokinetics in elderly</article-title><source>Nihon Ronen Igakkai Zasshi</source><year>2003</year><volume>40</volume><issue>2</issue><fpage>109</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.3143/geriatrics.40.109</pub-id><pub-id pub-id-type="pmid">12708041</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Tanigawara Y. Recent advances in pharmacokinetics in elderly. Nihon Ronen Igakkai Zasshi. 2003;40(2):109&#8211;19.<pub-id pub-id-type="pmid">12708041</pub-id><pub-id pub-id-type="doi">10.3143/geriatrics.40.109</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schlender</surname><given-names>JF</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>M</given-names></name><name name-style="western"><surname>Thelen</surname><given-names>K</given-names></name><name name-style="western"><surname>Krauss</surname><given-names>M</given-names></name><name name-style="western"><surname>Willmann</surname><given-names>S</given-names></name><name name-style="western"><surname>Eissing</surname><given-names>T</given-names></name><etal/></person-group><article-title>Development of a whole-body physiologically based Pharmacokinetic Approach to assess the pharmacokinetics of drugs in Elderly individuals</article-title><source>Clin Pharmacokinet</source><year>2016</year><volume>55</volume><issue>12</issue><fpage>1573</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1007/s40262-016-0422-3</pub-id><pub-id pub-id-type="pmid">27351180</pub-id><pub-id pub-id-type="pmcid">PMC5107207</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Schlender JF, Meyer M, Thelen K, Krauss M, Willmann S, Eissing T, et al. Development of a whole-body physiologically based Pharmacokinetic Approach to assess the pharmacokinetics of drugs in Elderly individuals. Clin Pharmacokinet. 2016;55(12):1573&#8211;89.<pub-id pub-id-type="pmid">27351180</pub-id><pub-id pub-id-type="doi">10.1007/s40262-016-0422-3</pub-id><pub-id pub-id-type="pmcid">PMC5107207</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guti&#233;rrez-Valencia</surname><given-names>M</given-names></name><name name-style="western"><surname>Izquierdo</surname><given-names>M</given-names></name><name name-style="western"><surname>Malafarina</surname><given-names>V</given-names></name><name name-style="western"><surname>Alonso-Renedo</surname><given-names>J</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Glar&#237;a</surname><given-names>B</given-names></name><name name-style="western"><surname>Larrayoz-Sola</surname><given-names>B</given-names></name><etal/></person-group><article-title>Impact of hospitalization in an acute geriatric unit on polypharmacy and potentially inappropriate prescriptions: a retrospective study</article-title><source>Geriatr Gerontol Int</source><year>2017</year><volume>17</volume><issue>12</issue><fpage>2354</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1111/ggi.13073</pub-id><pub-id pub-id-type="pmid">28422415</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Guti&#233;rrez-Valencia M, Izquierdo M, Malafarina V, Alonso-Renedo J, Gonz&#225;lez-Glar&#237;a B, Larrayoz-Sola B, et al. Impact of hospitalization in an acute geriatric unit on polypharmacy and potentially inappropriate prescriptions: a retrospective study. Geriatr Gerontol Int. 2017;17(12):2354&#8211;60.<pub-id pub-id-type="pmid">28422415</pub-id><pub-id pub-id-type="doi">10.1111/ggi.13073</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kojima</surname><given-names>T</given-names></name><name name-style="western"><surname>Akishita</surname><given-names>M</given-names></name><name name-style="western"><surname>Kameyama</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yamaguchi</surname><given-names>K</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>H</given-names></name><name name-style="western"><surname>Eto</surname><given-names>M</given-names></name><etal/></person-group><article-title>High risk of adverse drug reactions in elderly patients taking six or more drugs: analysis of inpatient database</article-title><source>Geriatr Gerontol Int</source><year>2012</year><volume>12</volume><issue>4</issue><fpage>761</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1111/j.1447-0594.2012.00868.x</pub-id><pub-id pub-id-type="pmid">22998384</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Kojima T, Akishita M, Kameyama Y, Yamaguchi K, Yamamoto H, Eto M, et al. High risk of adverse drug reactions in elderly patients taking six or more drugs: analysis of inpatient database. Geriatr Gerontol Int. 2012;12(4):761&#8211;2.<pub-id pub-id-type="pmid">22998384</pub-id><pub-id pub-id-type="doi">10.1111/j.1447-0594.2012.00868.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Ministry of Health, Labour and Welfare. Guidance of Appropriate Medication for Elderly Patients (General). 2018. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.pmda.go.jp/files/000232249.pdf">https://www.pmda.go.jp/files/000232249.pdf</ext-link>. Accessed May 1 2022.</mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Ministry of Health, Labour and Welfare. Guidance of Appropriate Medication for Elderly Patients [Particular (by Recuperation Environment)]. 2019. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.mhlw.go.jp/stf/newpage_05217.html">https://www.mhlw.go.jp/stf/newpage_05217.html</ext-link>. (only in Japanese) Accessed May 1 2022.</mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>D</given-names></name><name name-style="western"><surname>Steinberg</surname><given-names>J</given-names></name><name name-style="western"><surname>Patel</surname><given-names>P</given-names></name></person-group><article-title>Insomnia in the Elderly: a review</article-title><source>J Clin Sleep Med</source><year>2018</year><volume>14</volume><issue>6</issue><fpage>1017</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.5664/jcsm.7172</pub-id><pub-id pub-id-type="pmid">29852897</pub-id><pub-id pub-id-type="pmcid">PMC5991956</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Patel D, Steinberg J, Patel P. Insomnia in the Elderly: a review. J Clin Sleep Med. 2018;14(6):1017&#8211;24.<pub-id pub-id-type="pmid">29852897</pub-id><pub-id pub-id-type="doi">10.5664/jcsm.7172</pub-id><pub-id pub-id-type="pmcid">PMC5991956</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bain</surname><given-names>KT</given-names></name></person-group><article-title>Management of chronic insomnia in elderly persons</article-title><source>Am J Geriatr Pharmacother</source><year>2006</year><volume>4</volume><issue>2</issue><fpage>168</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.amjopharm.2006.06.006</pub-id><pub-id pub-id-type="pmid">16860264</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Bain KT. Management of chronic insomnia in elderly persons. Am J Geriatr Pharmacother. 2006;4(2):168&#8211;92.<pub-id pub-id-type="pmid">16860264</pub-id><pub-id pub-id-type="doi">10.1016/j.amjopharm.2006.06.006</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>MI</given-names></name><name name-style="western"><surname>Oleen</surname><given-names>MA</given-names></name></person-group><article-title>The use of benzodiazepine hypnotics in the elderly</article-title><source>Pharmacotherapy</source><year>1988</year><volume>8</volume><issue>4</issue><fpage>241</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1002/j.1875-9114.1988.tb04079.x</pub-id><pub-id pub-id-type="pmid">3194321</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Baker MI, Oleen MA. The use of benzodiazepine hypnotics in the elderly. Pharmacotherapy. 1988;8(4):241&#8211;7.<pub-id pub-id-type="pmid">3194321</pub-id><pub-id pub-id-type="doi">10.1002/j.1875-9114.1988.tb04079.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shorr</surname><given-names>RI</given-names></name><name name-style="western"><surname>Bauwens</surname><given-names>SF</given-names></name><name name-style="western"><surname>Landefeld</surname><given-names>CS</given-names></name></person-group><article-title>Failure to limit quantities of benzodiazepine hypnotic drugs for outpatients: placing the elderly at risk</article-title><source>Am J Med</source><year>1990</year><volume>89</volume><issue>6</issue><fpage>725</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/0002-9343(90)90213-W</pub-id><pub-id pub-id-type="pmid">2252041</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Shorr RI, Bauwens SF, Landefeld CS. Failure to limit quantities of benzodiazepine hypnotic drugs for outpatients: placing the elderly at risk. Am J Med. 1990;89(6):725&#8211;32.<pub-id pub-id-type="pmid">2252041</pub-id><pub-id pub-id-type="doi">10.1016/0002-9343(90)90213-W</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kojima</surname><given-names>T</given-names></name><name name-style="western"><surname>Mizukami</surname><given-names>K</given-names></name><name name-style="western"><surname>Tomita</surname><given-names>N</given-names></name><name name-style="western"><surname>Arai</surname><given-names>H</given-names></name><name name-style="western"><surname>Ohrui</surname><given-names>T</given-names></name><name name-style="western"><surname>Eto</surname><given-names>M</given-names></name><etal/></person-group><article-title>Screening Tool for older persons&#8217; appropriate prescriptions for Japanese: report of the Japan Geriatrics Society Working Group on Guidelines for medical treatment and its safety in the elderly</article-title><source>Geriatr Gerontol Int</source><year>2016</year><volume>16</volume><issue>9</issue><fpage>983</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.1111/ggi.12890</pub-id><pub-id pub-id-type="pmid">27594406</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Kojima T, Mizukami K, Tomita N, Arai H, Ohrui T, Eto M, et al. Screening Tool for older persons&#8217; appropriate prescriptions for Japanese: report of the Japan Geriatrics Society Working Group on Guidelines for medical treatment and its safety in the elderly. Geriatr Gerontol Int. 2016;16(9):983&#8211;1001.<pub-id pub-id-type="pmid">27594406</pub-id><pub-id pub-id-type="doi">10.1111/ggi.12890</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>G</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name></person-group><article-title>Association between Benzodiazepine Use and Dementia: a Meta-analysis</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><issue>5</issue><fpage>e0127836</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0127836</pub-id><pub-id pub-id-type="pmid">26016483</pub-id><pub-id pub-id-type="pmcid">PMC4446315</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Zhong G, Wang Y, Zhang Y, Zhao Y. Association between Benzodiazepine Use and Dementia: a Meta-analysis. PLoS ONE. 2015;10(5):e0127836.<pub-id pub-id-type="pmid">26016483</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0127836</pub-id><pub-id pub-id-type="pmcid">PMC4446315</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glass</surname><given-names>J</given-names></name><name name-style="western"><surname>Lanct&#244;t</surname><given-names>KL</given-names></name><name name-style="western"><surname>Herrmann</surname><given-names>N</given-names></name><name name-style="western"><surname>Sproule</surname><given-names>BA</given-names></name><name name-style="western"><surname>Busto</surname><given-names>UE</given-names></name></person-group><article-title>Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits</article-title><source>BMJ</source><year>2005</year><volume>331</volume><issue>7526</issue><fpage>1169</fpage><pub-id pub-id-type="doi">10.1136/bmj.38623.768588.47</pub-id><pub-id pub-id-type="pmid">16284208</pub-id><pub-id pub-id-type="pmcid">PMC1285093</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Glass J, Lanct&#244;t KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331(7526):1169.<pub-id pub-id-type="pmid">16284208</pub-id><pub-id pub-id-type="doi">10.1136/bmj.38623.768588.47</pub-id><pub-id pub-id-type="pmcid">PMC1285093</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenblatt</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Divoll</surname><given-names>M</given-names></name><name name-style="western"><surname>Abernethy</surname><given-names>DR</given-names></name><name name-style="western"><surname>Moschitto</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Smith</surname><given-names>RB</given-names></name><name name-style="western"><surname>Shader</surname><given-names>RI</given-names></name></person-group><article-title>Reduced clearance of triazolam in old age: relation to antipyrine oxidizing capacity</article-title><source>Br J Clin Pharmacol</source><year>1983</year><volume>15</volume><issue>3</issue><fpage>303</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.1983.tb01503.x</pub-id><pub-id pub-id-type="pmid">6133545</pub-id><pub-id pub-id-type="pmcid">PMC1427766</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Greenblatt DJ, Divoll M, Abernethy DR, Moschitto LJ, Smith RB, Shader RI. Reduced clearance of triazolam in old age: relation to antipyrine oxidizing capacity. Br J Clin Pharmacol. 1983;15(3):303&#8211;9.<pub-id pub-id-type="pmid">6133545</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2125.1983.tb01503.x</pub-id><pub-id pub-id-type="pmcid">PMC1427766</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klotz</surname><given-names>U</given-names></name><name name-style="western"><surname>Avant</surname><given-names>GR</given-names></name><name name-style="western"><surname>Hoyumpa</surname><given-names>A</given-names></name><name name-style="western"><surname>Schenker</surname><given-names>S</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>GR</given-names></name></person-group><article-title>The effects of age and liver disease on the disposition and elimination of diazepam in adult man</article-title><source>J Clin Invest</source><year>1975</year><volume>55</volume><issue>2</issue><fpage>347</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1172/JCI107938</pub-id><pub-id pub-id-type="pmid">1127104</pub-id><pub-id pub-id-type="pmcid">PMC301753</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Klotz U, Avant GR, Hoyumpa A, Schenker S, Wilkinson GR. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest. 1975;55(2):347&#8211;59.<pub-id pub-id-type="pmid">1127104</pub-id><pub-id pub-id-type="doi">10.1172/JCI107938</pub-id><pub-id pub-id-type="pmcid">PMC301753</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenblatt</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Harmatz</surname><given-names>JS</given-names></name><name name-style="western"><surname>von Moltke</surname><given-names>LL</given-names></name><name name-style="western"><surname>Wright</surname><given-names>CE</given-names></name><name name-style="western"><surname>Shader</surname><given-names>RI</given-names></name></person-group><article-title>Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate</article-title><source>Clin Pharmacol Ther</source><year>2004</year><volume>76</volume><issue>5</issue><fpage>467</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.clpt.2004.07.009</pub-id><pub-id pub-id-type="pmid">15536461</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Greenblatt DJ, Harmatz JS, von Moltke LL, Wright CE, Shader RI. Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clin Pharmacol Ther. 2004;76(5):467&#8211;79.<pub-id pub-id-type="pmid">15536461</pub-id><pub-id pub-id-type="doi">10.1016/j.clpt.2004.07.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenblatt</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Harmatz</surname><given-names>JS</given-names></name><name name-style="western"><surname>Shapiro</surname><given-names>L</given-names></name><name name-style="western"><surname>Engelhardt</surname><given-names>N</given-names></name><name name-style="western"><surname>Gouthro</surname><given-names>TA</given-names></name><name name-style="western"><surname>Shader</surname><given-names>RI</given-names></name></person-group><article-title>Sensitivity to triazolam in the elderly</article-title><source>N Engl J Med</source><year>1991</year><volume>324</volume><issue>24</issue><fpage>1691</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1056/NEJM199106133242403</pub-id><pub-id pub-id-type="pmid">2034245</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Greenblatt DJ, Harmatz JS, Shapiro L, Engelhardt N, Gouthro TA, Shader RI. Sensitivity to triazolam in the elderly. N Engl J Med. 1991;324(24):1691&#8211;8.<pub-id pub-id-type="pmid">2034245</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199106133242403</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bihan</surname><given-names>K</given-names></name><name name-style="western"><surname>Lebrun-Vignes</surname><given-names>B</given-names></name><name name-style="western"><surname>Funck-Brentano</surname><given-names>C</given-names></name><name name-style="western"><surname>Salem</surname><given-names>JE</given-names></name></person-group><article-title>Uses of pharmacovigilance databases: an overview</article-title><source>Therapie</source><year>2020</year><volume>75</volume><issue>6</issue><fpage>591</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.therap.2020.02.022</pub-id><pub-id pub-id-type="pmid">32169289</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Bihan K, Lebrun-Vignes B, Funck-Brentano C, Salem JE. Uses of pharmacovigilance databases: an overview. Therapie. 2020;75(6):591&#8211;8.<pub-id pub-id-type="pmid">32169289</pub-id><pub-id pub-id-type="doi">10.1016/j.therap.2020.02.022</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuemmel</surname><given-names>C</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Florian</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H</given-names></name><name name-style="western"><surname>Tegenge</surname><given-names>M</given-names></name><etal/></person-group><article-title>Consideration of a credibility Assessment Framework in Model-Informed Drug Development: potential application to physiologically-based pharmacokinetic modeling and Simulation</article-title><source>CPT Pharmacometrics Syst Pharmacol</source><year>2020</year><volume>9</volume><issue>1</issue><fpage>21</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1002/psp4.12479</pub-id><pub-id pub-id-type="pmid">31652029</pub-id><pub-id pub-id-type="pmcid">PMC6966181</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Kuemmel C, Yang Y, Zhang X, Florian J, Zhu H, Tegenge M, et al. Consideration of a credibility Assessment Framework in Model-Informed Drug Development: potential application to physiologically-based pharmacokinetic modeling and Simulation. CPT Pharmacometrics Syst Pharmacol. 2020;9(1):21&#8211;8.<pub-id pub-id-type="pmid">31652029</pub-id><pub-id pub-id-type="doi">10.1002/psp4.12479</pub-id><pub-id pub-id-type="pmcid">PMC6966181</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maeda</surname><given-names>K</given-names></name><name name-style="western"><surname>Hisaka</surname><given-names>A</given-names></name><name name-style="western"><surname>Ito</surname><given-names>K</given-names></name><name name-style="western"><surname>Ohno</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ishiguro</surname><given-names>A</given-names></name><name name-style="western"><surname>Sato</surname><given-names>R</given-names></name><etal/></person-group><article-title>Classification of drugs for evaluating drug interaction in drug development and clinical management</article-title><source>Drug Metab Pharmacokinet</source><year>2021</year><volume>41</volume><fpage>100414</fpage><pub-id pub-id-type="doi">10.1016/j.dmpk.2021.100414</pub-id><pub-id pub-id-type="pmid">34666290</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Maeda K, Hisaka A, Ito K, Ohno Y, Ishiguro A, Sato R, et al. Classification of drugs for evaluating drug interaction in drug development and clinical management. Drug Metab Pharmacokinet. 2021;41:100414.<pub-id pub-id-type="pmid">34666290</pub-id><pub-id pub-id-type="doi">10.1016/j.dmpk.2021.100414</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Guideline on drug interaction for drug development and appropriate provision of information. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.pmda.go.jp/files/000228122.pdf">https://www.pmda.go.jp/files/000228122.pdf</ext-link>. Accessed May 1 2022.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.dmpk.2019.11.009</pub-id><pub-id pub-id-type="pmid">31902469</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">HALCION (TRIAZOLAM). Label - FDA (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/">https://www.accessdata.fda.gov/</ext-link>, Accessed 2021-10-22).</mixed-citation></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schou</surname><given-names>JS</given-names></name></person-group><article-title>Triazolam: adverse effects in relation to dosage</article-title><source>Pharmacol Toxicol</source><year>1989</year><volume>64</volume><issue>1</issue><fpage>6</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/j.1600-0773.1989.tb00590.x</pub-id><pub-id pub-id-type="pmid">2755912</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Schou JS. Triazolam: adverse effects in relation to dosage. Pharmacol Toxicol. 1989;64(1):6&#8211;8.<pub-id pub-id-type="pmid">2755912</pub-id><pub-id pub-id-type="doi">10.1111/j.1600-0773.1989.tb00590.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanda</surname><given-names>Y</given-names></name></person-group><article-title>Investigation of the freely available easy-to-use software &#8216;EZR&#8217; for medical statistics</article-title><source>Bone Marrow Transpl</source><year>2013</year><volume>48</volume><issue>3</issue><fpage>452</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/bmt.2012.244</pub-id><pub-id pub-id-type="pmcid">PMC3590441</pub-id><pub-id pub-id-type="pmid">23208313</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Kanda Y. Investigation of the freely available easy-to-use software &#8216;EZR&#8217; for medical statistics. Bone Marrow Transpl. 2013;48(3):452&#8211;8.<pub-id pub-id-type="doi">10.1038/bmt.2012.244</pub-id><pub-id pub-id-type="pmcid">PMC3590441</pub-id><pub-id pub-id-type="pmid">23208313</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barbhaiya</surname><given-names>RH</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>UA</given-names></name><name name-style="western"><surname>Kroboth</surname><given-names>PD</given-names></name><name name-style="western"><surname>Greene</surname><given-names>DS</given-names></name></person-group><article-title>Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam</article-title><source>J Clin Psychopharmacol</source><year>1995</year><volume>15</volume><issue>5</issue><fpage>320</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1097/00004714-199510000-00003</pub-id><pub-id pub-id-type="pmid">8830062</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS. Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. J Clin Psychopharmacol. 1995;15(5):320&#8211;6.<pub-id pub-id-type="pmid">8830062</pub-id><pub-id pub-id-type="doi">10.1097/00004714-199510000-00003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenblatt</surname><given-names>DJ</given-names></name><name name-style="western"><surname>von Moltke</surname><given-names>LL</given-names></name><name name-style="western"><surname>Harmatz</surname><given-names>JS</given-names></name><name name-style="western"><surname>Counihan</surname><given-names>M</given-names></name><name name-style="western"><surname>Graf</surname><given-names>JA</given-names></name><name name-style="western"><surname>Durol</surname><given-names>AL</given-names></name><etal/></person-group><article-title>Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences</article-title><source>Clin Pharmacol Ther</source><year>1998</year><volume>64</volume><issue>3</issue><fpage>278</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/S0009-9236(98)90176-X</pub-id><pub-id pub-id-type="pmid">9757151</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Greenblatt DJ, von Moltke LL, Harmatz JS, Counihan M, Graf JA, Durol AL, et al. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin Pharmacol Ther. 1998;64(3):278&#8211;85.<pub-id pub-id-type="pmid">9757151</pub-id><pub-id pub-id-type="doi">10.1016/S0009-9236(98)90176-X</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Warot</surname><given-names>D</given-names></name><name name-style="western"><surname>Bergougnan</surname><given-names>L</given-names></name><name name-style="western"><surname>Lamiable</surname><given-names>D</given-names></name><name name-style="western"><surname>Berlin</surname><given-names>I</given-names></name><name name-style="western"><surname>Bensimon</surname><given-names>G</given-names></name><name name-style="western"><surname>Danjou</surname><given-names>P</given-names></name><etal/></person-group><article-title>Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation</article-title><source>Eur J Clin Pharmacol</source><year>1987</year><volume>32</volume><issue>4</issue><fpage>389</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1007/BF00543975</pub-id><pub-id pub-id-type="pmid">3497041</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Warot D, Bergougnan L, Lamiable D, Berlin I, Bensimon G, Danjou P, et al. Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation. Eur J Clin Pharmacol. 1987;32(4):389&#8211;93.<pub-id pub-id-type="pmid">3497041</pub-id><pub-id pub-id-type="doi">10.1007/BF00543975</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ochs</surname><given-names>HR</given-names></name><name name-style="western"><surname>Greenblatt</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Kn&#252;chel</surname><given-names>M</given-names></name></person-group><article-title>Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation</article-title><source>Br J Clin Pharmacol</source><year>1983</year><volume>16</volume><issue>6</issue><fpage>743</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.1983.tb02256.x</pub-id><pub-id pub-id-type="pmid">6140941</pub-id><pub-id pub-id-type="pmcid">PMC1428351</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Ochs HR, Greenblatt DJ, Kn&#252;chel M. Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation. Br J Clin Pharmacol. 1983;16(6):743&#8211;6.<pub-id pub-id-type="pmid">6140941</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2125.1983.tb02256.x</pub-id><pub-id pub-id-type="pmcid">PMC1428351</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varhe</surname><given-names>A</given-names></name><name name-style="western"><surname>Olkkola</surname><given-names>KT</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name></person-group><article-title>Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole</article-title><source>Clin Pharmacol Ther</source><year>1994</year><volume>56</volume><issue>6 Pt 1</issue><fpage>601</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1038/clpt.1994.184</pub-id><pub-id pub-id-type="pmid">7995001</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994;56(6 Pt 1):601&#8211;7.<pub-id pub-id-type="pmid">7995001</pub-id><pub-id pub-id-type="doi">10.1038/clpt.1994.184</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varhe</surname><given-names>A</given-names></name><name name-style="western"><surname>Olkkola</surname><given-names>KT</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name></person-group><article-title>Effect of fluconazole dose on the extent of fluconazole-triazolam interaction</article-title><source>Br J Clin Pharmacol</source><year>1996</year><volume>42</volume><issue>4</issue><fpage>465</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.1996.tb00009.x</pub-id><pub-id pub-id-type="pmid">8904618</pub-id><pub-id pub-id-type="pmcid">PMC2042698</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Varhe A, Olkkola KT, Neuvonen PJ. Effect of fluconazole dose on the extent of fluconazole-triazolam interaction. Br J Clin Pharmacol. 1996;42(4):465&#8211;70.<pub-id pub-id-type="pmid">8904618</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2125.1996.tb00009.x</pub-id><pub-id pub-id-type="pmcid">PMC2042698</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Culm-Merdek</surname><given-names>KE</given-names></name><name name-style="western"><surname>von Moltke</surname><given-names>LL</given-names></name><name name-style="western"><surname>Gan</surname><given-names>L</given-names></name><name name-style="western"><surname>Horan</surname><given-names>KA</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>R</given-names></name><name name-style="western"><surname>Harmatz</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir</article-title><source>Clin Pharmacol Ther</source><year>2006</year><volume>79</volume><issue>3</issue><fpage>243</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.clpt.2005.11.009</pub-id><pub-id pub-id-type="pmid">16513448</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Culm-Merdek KE, von Moltke LL, Gan L, Horan KA, Reynolds R, Harmatz JS, et al. Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clin Pharmacol Ther. 2006;79(3):243&#8211;54.<pub-id pub-id-type="pmid">16513448</pub-id><pub-id pub-id-type="doi">10.1016/j.clpt.2005.11.009</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pourbaix</surname><given-names>S</given-names></name><name name-style="western"><surname>Desager</surname><given-names>JP</given-names></name><name name-style="western"><surname>Hulhoven</surname><given-names>R</given-names></name><name name-style="western"><surname>Smith</surname><given-names>RB</given-names></name><name name-style="western"><surname>Harvengt</surname><given-names>C</given-names></name></person-group><article-title>Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects</article-title><source>Int J Clin Pharmacol Ther Toxicol</source><year>1985</year><volume>23</volume><issue>8</issue><fpage>447</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">2864320</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Pourbaix S, Desager JP, Hulhoven R, Smith RB, Harvengt C. Pharmacokinetic consequences of long term coadministration of cimetidine and triazolobenzodiazepines, alprazolam and triazolam, in healthy subjects. Int J Clin Pharmacol Ther Toxicol. 1985;23(8):447&#8211;51.<pub-id pub-id-type="pmid">2864320</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Connor-Semmes</surname><given-names>RL</given-names></name><name name-style="western"><surname>Kersey</surname><given-names>K</given-names></name><name name-style="western"><surname>Williams</surname><given-names>DH</given-names></name><name name-style="western"><surname>Lam</surname><given-names>R</given-names></name><name name-style="western"><surname>Koch</surname><given-names>KM</given-names></name></person-group><article-title>Effect of ranitidine on the pharmacokinetics of triazolam and alpha-hydroxytriazolam in both young (19&#8211;60 years) and older (61&#8211;78 years) people</article-title><source>Clin Pharmacol Ther</source><year>2001</year><volume>70</volume><issue>2</issue><fpage>126</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1067/mcp.2001.117120</pub-id><pub-id pub-id-type="pmid">11503006</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">O&#8217;Connor-Semmes RL, Kersey K, Williams DH, Lam R, Koch KM. Effect of ranitidine on the pharmacokinetics of triazolam and alpha-hydroxytriazolam in both young (19&#8211;60 years) and older (61&#8211;78 years) people. Clin Pharmacol Ther. 2001;70(2):126&#8211;31.<pub-id pub-id-type="pmid">11503006</pub-id><pub-id pub-id-type="doi">10.1067/mcp.2001.117120</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Backman</surname><given-names>JT</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JS</given-names></name><name name-style="western"><surname>Wen</surname><given-names>X</given-names></name><name name-style="western"><surname>Kivist&#246;</surname><given-names>KT</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name></person-group><article-title>Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam</article-title><source>Clin Pharmacol Ther</source><year>1999</year><volume>66</volume><issue>4</issue><fpage>401</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1053/cp.1999.v66.a101461</pub-id><pub-id pub-id-type="pmid">10546924</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Backman JT, Wang JS, Wen X, Kivist&#246; KT, Neuvonen PJ. Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam. Clin Pharmacol Ther. 1999;66(4):401&#8211;7.<pub-id pub-id-type="pmid">10546924</pub-id><pub-id pub-id-type="doi">10.1053/cp.1999.v66.a101461</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varhe</surname><given-names>A</given-names></name><name name-style="western"><surname>Olkkola</surname><given-names>KT</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name></person-group><article-title>Diltiazem enhances the effects of triazolam by inhibiting its metabolism</article-title><source>Clin Pharmacol Ther</source><year>1996</year><volume>59</volume><issue>4</issue><fpage>369</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/S0009-9236(96)90103-4</pub-id><pub-id pub-id-type="pmid">8612379</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Varhe A, Olkkola KT, Neuvonen PJ. Diltiazem enhances the effects of triazolam by inhibiting its metabolism. Clin Pharmacol Ther. 1996;59(4):369&#8211;75.<pub-id pub-id-type="pmid">8612379</pub-id><pub-id pub-id-type="doi">10.1016/S0009-9236(96)90103-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lilja</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Kivist&#246;</surname><given-names>KT</given-names></name><name name-style="western"><surname>Backman</surname><given-names>JT</given-names></name><name name-style="western"><surname>Neuvonen</surname><given-names>PJ</given-names></name></person-group><article-title>Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life</article-title><source>Eur J Clin Pharmacol</source><year>2000</year><volume>56</volume><issue>5</issue><fpage>411</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1007/s002280000156</pub-id><pub-id pub-id-type="pmid">11009051</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Lilja JJ, Kivist&#246; KT, Backman JT, Neuvonen PJ. Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life. Eur J Clin Pharmacol. 2000;56(5):411&#8211;5.<pub-id pub-id-type="pmid">11009051</pub-id><pub-id pub-id-type="doi">10.1007/s002280000156</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stoehr</surname><given-names>GP</given-names></name><name name-style="western"><surname>Kroboth</surname><given-names>PD</given-names></name><name name-style="western"><surname>Juhl</surname><given-names>RP</given-names></name><name name-style="western"><surname>Wender</surname><given-names>DB</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>JP</given-names></name><name name-style="western"><surname>Smith</surname><given-names>RB</given-names></name></person-group><article-title>Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics</article-title><source>Clin Pharmacol Ther</source><year>1984</year><volume>36</volume><issue>5</issue><fpage>683</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1038/clpt.1984.240</pub-id><pub-id pub-id-type="pmid">6149030</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Stoehr GP, Kroboth PD, Juhl RP, Wender DB, Phillips JP, Smith RB. Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics. Clin Pharmacol Ther. 1984;36(5):683&#8211;90.<pub-id pub-id-type="pmid">6149030</pub-id><pub-id pub-id-type="doi">10.1038/clpt.1984.240</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kannus</surname><given-names>P</given-names></name><name name-style="western"><surname>Siev&#228;nen</surname><given-names>H</given-names></name><name name-style="western"><surname>Palvanen</surname><given-names>M</given-names></name><name name-style="western"><surname>J&#228;rvinen</surname><given-names>T</given-names></name><name name-style="western"><surname>Parkkari</surname><given-names>J</given-names></name></person-group><article-title>Prevention of falls and consequent injuries in elderly people</article-title><source>Lancet</source><year>2005</year><volume>366</volume><issue>9500</issue><fpage>1885</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)67604-0</pub-id><pub-id pub-id-type="pmid">16310556</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Kannus P, Siev&#228;nen H, Palvanen M, J&#228;rvinen T, Parkkari J. Prevention of falls and consequent injuries in elderly people. Lancet. 2005;366(9500):1885&#8211;93.<pub-id pub-id-type="pmid">16310556</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(05)67604-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masudo</surname><given-names>C</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>N</given-names></name><name name-style="western"><surname>Mihara</surname><given-names>K</given-names></name></person-group><article-title>Association between Elimination Half-life of benzodiazepines and falls in the Elderly: a Meta-analysis of Observational studies</article-title><source>Yakugaku Zasshi</source><year>2019</year><volume>139</volume><issue>1</issue><fpage>113</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1248/yakushi.18-00156</pub-id><pub-id pub-id-type="pmid">30606917</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Masudo C, Ogawa Y, Yamashita N, Mihara K. Association between Elimination Half-life of benzodiazepines and falls in the Elderly: a Meta-analysis of Observational studies. Yakugaku Zasshi. 2019;139(1):113&#8211;22.<pub-id pub-id-type="pmid">30606917</pub-id><pub-id pub-id-type="doi">10.1248/yakushi.18-00156</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wienkers</surname><given-names>LC</given-names></name><name name-style="western"><surname>Heath</surname><given-names>TG</given-names></name></person-group><article-title>Predicting in vivo drug interactions from in vitro drug discovery data</article-title><source>Nat Rev Drug Discov</source><year>2005</year><volume>4</volume><issue>10</issue><fpage>825</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1038/nrd1851</pub-id><pub-id pub-id-type="pmid">16224454</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov. 2005;4(10):825&#8211;33.<pub-id pub-id-type="pmid">16224454</pub-id><pub-id pub-id-type="doi">10.1038/nrd1851</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>